Increased monocyte tissue factor expression in coronary disease

E W Leatham, P M W Bath, J A Tooze, A J Camm

Abstract

Objective—To investigate whether monocyte expression of tissue factor is increased in patients with acute coronary syndromes and chronic stable angina.

Design—Cross sectional study of monocyte tissue factor expression in patients with ischaemic heart disease and control subjects.

Background—Unstable angina and myocardial infarction are associated with enhanced mononuclear cell procoagulant activity. Procoagulant activity of blood monocytes is principally mediated by tissue factor expression. Tissue factor initiates the coagulation cascade, and monocyte tissue factor expression may therefore be increased in these syndromes.

Methods—Monocyte tissue factor expression was measured cytotmetrically in whole blood flow using a polyclonal rabbit anti-human tissue factor antibody.

Patients—30 patients with acute myocardial infarction, 17 with unstable angina, 13 with chronic stable angina, and 11 normal control subjects.

Results—Increased proportions of monocytes expressing tissue factor (>2.5%) were found in none of 11 (0%) normal subjects, five of 13 (38%) patients with stable angina, 11 of 17 (64%) patients with unstable angina, and 16 of 30 (53%) patients with myocardial infarction (2P = 0.006). Blood from all subjects showed similar monocyte tissue factor expression (46.1 (15.1)%) after lipopolysaccharide stimulation.

Conclusion—Hypercoagulability associated with acute myocardial infarction, unstable angina, and chronic stable angina may be induced by tissue factor expressed on circulating monocytes.

Keywords: monocytes, tissue factor, coronary heart disease.

Monocytes exhibit marked procoagulant activity in vitro after stimulation with endotoxin,\textsuperscript{1} tumour necrosis factor,\textsuperscript{2} and a wide variety of other immunological and inflammatory stimuli.\textsuperscript{3,4} Similarly procoagulant activity has been described in monocytes isolated from animals injected with endotoxin\textsuperscript{5} and in humans presenting with various medical disorders associated with hypercoagulability.\textsuperscript{6-11} Enhanced procoagulant activity has also been described in monocytes from patients with unstable angina, where the degree of procoagulant activity was found to correlate with markers of thrombin production.\textsuperscript{12}

Mononuclear cell procoagulant activity is mediated by the expression of tissue factor on the surface of monocytes.\textsuperscript{13,14} Tissue factor is a 47 kDa integral membrane glycoprotein made up of 263 amino acids. Tissue factor binds to coagulation factor VIIa, initiating intrinsic and extrinsic pathways of the coagulation cascade.\textsuperscript{15,16}

A mononuclear procoagulant assay measures the ability of mononuclear cells to clot plasma, and is relatively non-specific. The technique is time consuming because mononuclear cells have to be separated from plasma and erythrocytes. Instead, we have measured tissue factor expression on monocytes in whole blood using polyclonal rabbit antibodies raised against recombinant human tissue factor. Precise measurement of antibody binding to the surface of monocytes was achieved using flow cytometry.

Patients and methods

PATIENTS

Thirty consecutive patients with acute myocardial infarction (24 Q wave, six non-Q wave), and 17 with unstable angina admitted to the coronary care unit were studied between February and October 1993. In addition, 13 patients with stable, but severe, angina requiring elective revascularisation (coronary artery bypass surgery 10, percutaneous transluminal coronary angioplasty 3) and 11 normal control subjects were studied. Myocardial infarction and unstable angina (spontaneous angina) were defined using standard World Health Organisation criteria.\textsuperscript{17} This definition includes patients with symptoms of coronary ischaemia at rest, but does not include deteriorating angina on exertion. Patients presenting with acute coronary syndromes were only included if coronary chest pain lasting more than 10 minutes had occurred at rest within 24 hours of blood sampling, although the original onset of chest pain may have occurred days before. In addition, only patients with unstable angina associated with transient electrocardiographic changes were selected (ST segment or T wave changes).

Eleven control subjects were selected from consecutive patients attending the outpatient phlebotomy room for “screening” blood tests arranged by general practitioners; these were in good health and receiving no drugs. We...
Increased monocyte tissue factor expression in coronary disease

excluded all patients with clinically obvious intercurrent infection, malignancy, or other serious medical disorders. The study protocol was approved by St George’s Hospital medical ethics committee.

SAMPLE COLLECTION
Demographic and medical details (table including type of myocardial infarction and interval between onset of chest pain and blood sampling were collected. A single sample of blood was collected from each patient between 8 and 10 am. Two millilitres of venous blood was drawn from a 19 gauge butterfly into a prechilled, heparinized syringe and kept on melting ice until analysis. Half the blood was stimulated with 10 μg/ml lipopolysaccharide (Sigma, Luton, United Kingdom) for three hours to assess the maximum potential of monocytes to express tissue factor.

MEASUREMENT OF MONOCYTE TISSUE FACTOR EXPRESSION
A 100 μl volume of unstimulated or lipopolysaccharide stimulated blood was incubated with 2 μg of rabbit antihuman tissue factor for 30 minutes at 4°C. This rabbit antihuman antibody was shown previously to have high specificity for human tissue factor in western blot experiments, and blocked the functional activity of tissue factor in procoagulant assays.

Red cells were lysed with Q-prep solutions (Coulter Corporation, Luton, United Kingdom). Cells were washed twice in chilled phosphate buffered saline before incubating with fluorescein conjugated swine antirabbit antibody for 30 minutes. Cells were rewarshed twice and fixed with 1% paraformaldehyde before flow cytometric analysis.

Non-specific binding of antibodies was assessed for the primary and secondary antibodies, using irrelevant control antibodies (rabbit antichicken and swine antirabbit antibodies respectively). These controls allowed us to find an appropriate threshold of surface fluorescence on unstimulated cells from normal subjects, above which only low levels (≤2-5%) of non-specific binding occurred.

FLOW CYTOMETRY
A Becton Dickinson flow cytometer (FacScan), Becton Dickinson, Mountain View, California, USA) was used to measure monocyte tissue factor expression. Leucocytes were gated on forward and side scatter. Pilot experiments showed the monocyte population to be CD14 (Coulter) positive (92% (5%)).

Leucocyte surface fluorescence was measured using 10,000 cells for each sample.

After the determination of tissue factor expression in normal subjects, we set a threshold value of 2-5% tissue factor positive cells, based on measurement of six normal laboratory staff, who all had tissue factor expression <2-5% (median (IQR) 1.1 (0-2)). Patients with <2-5% positive cells were considered negative for tissue factor, patients with >2-5% positive cells were considered positive.

The flow cytometer was calibrated each day with calibration beads (CMPC, Hato Rey, Puerto Rico), which enabled the threshold for the detection of monocyte tissue factor to be standardised for each measurement.

STATISTICAL ANALYSIS
The patient characteristics are described using the median and interquartile range. Comparisons were made using the Kruskal-Wallis for multiple group data and the χ² test for frequency data. Probability values of P < 0-05 (Kruskal-Wallis) or 2P < 0-05 (χ²) were considered significant.

Results
PATIENT CHARACTERISTICS
The four patient groups were matched, with no difference found for age, race, gender, and interval between the initial onset of chest pain and time of blood sampling (table).

MONOCYTE TISSUE FACTOR EXPRESSION
Increased tissue factor expression was observed in 32 of the 71 patients studied. Figure 1 shows representative histograms of surface tissue factor expression in one patient with myocardial infarction and one normal control. All normal control subjects had a low proportion (≤2-5%) of tissue factor positive cells (fig 2). In contrast, patients with chronic stable angina, unstable angina, and myocardial infarction showed variable proportions of monocytes expressing tissue factor (fig 2).

Specifically, none of 11 (0%) normal subjects, five of 13 (38%) patients with stable angina, 11 of 17 (64%) patients with unstable angina, and 16 of 30 (53%) patients with myocardial infarction had increased proportions of tissue factor positive monocytes. These proportions were significantly different between groups (χ² = 12.7, 2P = 0.006, df = 3). Further analysis showed a trend of increasing tissue factor expression with increasing severity (ordered as normal, angina, unstable angina, myocardial infarction (χ² = 8.2, 2P = 0.005, df = 1)). In contrast, stimulation of blood with lipopolysaccharide caused an increase in the proportion of monocytes expressing tissue factor to above 2-5% in all subjects (fig 3).

The mean (SD) percentage positivity was 46.1 (15.1)% of leucocytes, which was not significant between groups (P = 0.86).

<p>| Table: Patient demographic details. Median value (interquartile range) of frequency (percentage). Comparisons made using Kruskal-Wallis test or χ² test. P &lt; 0-05 and 2P &lt; 0-05 respectively considered significant. |</p>
<table>
<thead>
<tr>
<th>Myocardial infarction (n = 30)</th>
<th>Unstable angina (n = 17)</th>
<th>Chronic stable angina (n = 13)</th>
<th>Normal controls (n = 11)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60 (15)</td>
<td>61 (20)</td>
<td>67 (17)</td>
<td>51 (21)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>25 (83)</td>
<td>13 (76)</td>
<td>12 (92)</td>
<td>7 (64)</td>
</tr>
<tr>
<td>White (%)</td>
<td>28 (93)</td>
<td>14 (82)</td>
<td>13 (100)</td>
<td>8 (72)</td>
</tr>
<tr>
<td>Smokers (%)</td>
<td>11 (37)</td>
<td>5 (29)</td>
<td>1 (8)</td>
<td>2 (18)</td>
</tr>
</tbody>
</table>

Time between first onset of symptoms and study entry (hours) 25 (20) 25 (37) — — 0.91

*Smokers: current or within one month.
Discussion
Flow cytometric measurement of tissue factor expressed by ficoll separated monocytes has previously been shown to correlate well with monocyte procoagulant activity. The method has been used to show enhanced tissue factor production by monocytes in neonatal infection. Although a whole blood technique is now common practice for labelling blood cells with other antibodies, we are the first to describe a whole blood method for assessing monocyte tissue factor expression.

Our method has two advantages over conventional techniques requiring cell separation. Firstly, the time taken to label monocytes is short and the test is therefore more convenient. Secondly, the rapid incubation at 4°C reduces the chance of sample contamination with endotoxin, which would cause an artefactual increase in monocyte tissue factor expression.

We have shown for the first time that monocyte tissue factor expression is increased in patients with acute coronary syndromes and chronic stable angina. Neri Serneri et al. have shown that separated mononuclear cells show increased procoagulant or 'tissue factor like' activity in tissue cultured monocytes of patients with unstable angina compared with convalescent and normal control samples. One other report of increased monocyte related procoagulant activity in unstable angina has been published in abstract form. Our studies indicate that such mononuclear cell procoagulant effects are mediated, in part, by tissue factor expressed on monocytes.

Both intrinsic and extrinsic coagulation pathways are activated by tissue factor. Thus tissue factor expression on circulating monocytes will cause a systemic procoagulant state, which may have a role in atherothrombosis. Furthermore, as monocyte adhesion, migration, and transformation into tissue macrophages is known to occur at the site of atherosclerotic plaque, focal production of tissue factor may explain the propensity for thrombosis at the site of atherosclerosis.

The cause of increased tissue factor expression in patients with coronary disease is currently unclear. One possible explanation is that tissue factor expression is reactive or follows tissue necrosis. This is unlikely to explain all of our findings, as tissue factor expression was increased in patients with unstable angina and chronic stable angina, where recent monocyte necrosis had not occurred. Furthermore, tissue factor expression did not correlate with C reactive protein, an acute phase reactant, when 28 patients were tested (data not shown). Alternatively, or in addition, an increase in monocyte tissue factor expression may precede acute coronary syndromes and predispose to their development. One possible sequence of events is that infection precedes acute coronary ischaemia and thereby leads to an increase in monocyte tissue factor expression. For example, there have been several reports showing an association between *Chlamydia pneumoniae* infection and coronary disease. Monocyte tissue factor expression can be induced in vitro by a variety of stimuli including bacterial endotoxins, soluble immune complexes, lectins, lymphokines, viruses, and chemically modified low density lipoprotein. Similar stimulation may occur in response to infection in vivo. Thus infection may lead to enhanced monocyte tissue factor expression, which induces a hypercoagulable state.

The hypothesis that a population of hyperfunctional monocytes is produced before myocardial infarction (perhaps secondary to
infection), with enhanced potential for expressing tissue factor, is a less likely explanation as our patients' monocytes did not express more tissue factor than controls after lipopolysaccharide stimulation. A limitation of the study is that we did not test monocyte tissue factor expression after incubation with a range of various concentrations of lipopolysaccharide; hence it is possible that differences in the responsiveness of monocytes to lipopolysaccharide could have been missed by testing at a single lipopolysaccharide concentration. Increased mononuclear cell procoagulant activity in unstable angina was found by Neri Serneri et al to return to a normal baseline over four weeks. We have shown increased expression of monocyte tissue factor in a small number of patients with chronic stable angina. Our observation suggests that the phenomenon of enhanced monocyte tissue factor expression may be less transient than expected. The increased concentrations observed in these patients should be regarded with caution, however, as they all had severe coronary artery disease requiring intervention and hence were not representative of most patients with chronic stable angina.

It is interesting to note that not all patients with acute coronary syndromes showed an increase in the percentage of tissue factor positive monocytes. This does not invalidate the hypothesis that monocytes initiate thrombosis as tissue factor expression is only one of several leucocyte mechanisms known to induce thrombosis. Monocytes have been shown to produce several constituents of the clotting cascade, including factors V, VII, VIII, Mac-1 dependent factor X, and prothrombinase.

In summary, acute and chronic coronary syndromes are associated with increased tissue factor expression. As tissue factor initiates the clotting cascade, it is possible that an element of coronary thrombosis in coronary artery disease is induced by activated monocytes. This could potentiate thrombosis related to platelet aggregation and adhesion to the endothelium after the rupture of a coronary plaque.

We thank Dr E Tuddenham and Dr D Martin, Thrombosis Research Group, Clinical Research Centre, Northwick Park Hospital, Harrow, Middlesex for supplying the rabbit anti-human tissue factor and rabbit antichicken antibodies. We thank Professor GA MacGregor, BPU and the University of London Central Research Fund for financial support of the project, and Dr M de Belder for his help with the manuscript. Part of this work was presented at the American Heart Association, Atlanta, 1993.


